Unavailable
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $VRNA
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/21/2025 | $80.00 | Overweight | Cantor Fitzgerald |
| 1/10/2025 | $68.00 | Buy | ROTH MKM |
| 10/3/2024 | $50.00 | Overweight | Wells Fargo |
| 5/22/2023 | $35.00 → $38.00 | Buy | Jefferies |
| 9/19/2022 | $27.00 | Outperform | Wedbush |
| 8/26/2022 | $31.00 | Overweight | Piper Sandler |
| 11/12/2021 | $18.00 → $23.00 | Buy | Canaccord Genuity |
| 9/13/2021 | $25.00 | Buy | HC Wainwright & Co. |
Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp
Xeris Announces Changes to Its Board of Directors
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy. In addition, John Schmid has decided not to stand for re-election at the Company's 2025 Annual Stockholders Meeting, at which time the size of the Board will be reduced to eight members. "I am honored to welcome Jim to our Board of Direc
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement ("RIPSA") and increasing the debt facility to $450 million on improved terms with funds managed by Oaktree Capital Management, L.P. ("Oaktree") and OMERS Life Sciences ("OMERS") announced in May 2024. "We are pleased that Oaktree and OMERS recog
Cantor Fitzgerald initiated coverage on Verona Pharma with a new price target
Cantor Fitzgerald initiated coverage of Verona Pharma with a rating of Overweight and set a new price target of $80.00
ROTH MKM initiated coverage on Verona Pharma with a new price target
ROTH MKM initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $68.00
Wells Fargo initiated coverage on Verona Pharma with a new price target
Wells Fargo initiated coverage of Verona Pharma with a rating of Overweight and set a new price target of $50.00
Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)
4 - Verona Pharma plc (0001657312) (Issuer)
Director Ebsworth David R bought $188,881 worth of Ordinary Shares (39,360 units at $4.80), increasing direct ownership by 4% to 920,003 units (SEC Form 4)
4 - Verona Pharma plc (0001657312) (Issuer)
Director Ackermann Christina bought $198,386 worth of Ordinary Shares (41,880 units at $4.74) (SEC Form 4)
4 - Verona Pharma plc (0001657312) (Issuer)
Chief Medical Officer Rickard Kathleen A. sold $661,942 worth of Ordinary Shares (79,264 units at $8.35), decreasing direct ownership by 3% to 2,608,976 units (SEC Form 4)
4 - Verona Pharma plc (0001657312) (Issuer)
Director Ebsworth David R exercised 460,000 units of Ordinary Shares at a strike of $1.30 and gifted 64,000 units of Ordinary Shares, increasing direct ownership by 42% to 1,336,003 units (SEC Form 4)
4 - Verona Pharma plc (0001657312) (Issuer)
President and CEO Zaccardelli David covered exercise/tax liability with 166,728 units of Ordinary Shares and was granted 200,000 units of Ordinary Shares, increasing direct ownership by 0.23% to 14,238,024 units (SEC Form 4)
4 - Verona Pharma plc (0001657312) (Issuer)
Verona Pharma plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - Verona Pharma plc (0001657312) (Filer)
SEC Form DEF 14A filed by Verona Pharma plc
DEF 14A - Verona Pharma plc (0001657312) (Filer)
SEC Form S-8 filed by Verona Pharma plc
S-8 - Verona Pharma plc (0001657312) (Filer)
Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board
Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2021, and provides a corporate update. "The first quarter of 2021 set a positive tone for what we expect to be another exciting year of substantial progress for Verona Pharma," said David Zaccardelli, Pharm. D., President and Chief E
Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provide
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-836-8184 for callers in the United States+1-646-357-8785 for international callers A live webcast will be available on the Events and Presentations link on the Investors p
Amendment: SEC Form SC 13G/A filed by Verona Pharma plc
SC 13G/A - Verona Pharma plc (0001657312) (Subject)
Amendment: SEC Form SC 13G/A filed by Verona Pharma plc
SC 13G/A - Verona Pharma plc (0001657312) (Subject)
SEC Form SC 13G filed by Verona Pharma plc
SC 13G - Verona Pharma plc (0001657312) (Subject)